'US pressure to deregulate medicine markets no doubt speeds up access to new drugs. But the rationale isn’t always to help patients. It often has more to do with the economic interests of countries with a strong research-based pharmaceutical industry.'
Narcyz Ghineao, Doctoral Researcher, Centre for Values, Ethics and the Law in Medicine and Wendy Lipworth, Senior Research Fellow, Bioethics, both from the University of Sydney, look at the dangers of deregulation and the forces at play behind this US push to speed new drug assessments: theconversation.com/faster-...
Neil